Company intelligence / Profile preview
Secarna Pharmaceuticals
Planegg-Martinsried/Munich area, Bavaria, Germanysecarna.com ↗
- Ownership
- Private
- Employees
- ~16
- Development stage
- Preclinical
01
Overview
Secarna’s lead asset SECN‑15 (an antisense oligonucleotide targeting NRP1) has shown strong preclinical efficacy as monotherapy and in combination with immune checkpoint inhibitors. In animal models of solid tumors including gastric cancer, SECN‑15 delayed or eradicated tumor growth and enhanced the effect of ICIs. First-in-human trials are planned to start mid‑2026.
- Therapeutic areas
- OncologyImmunologyOtherCardiovascularNeurologyInfectious Diseases
- Modalities
- Antisense oligonucleotides (ASOs)Peptide-conjugated ASOs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Orbit Discovery Ltd. – peptide-conjugated targeted ASO therapeutics collaborationSciNeuro Pharmaceuticals – multi-target CNS disease research partnershipEvotec – commercial partnering transactionDenali Therapeutics – commercial partnering transaction
Beyond the preview
Go deeper on Secarna Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Secarna Pharmaceuticals.